Anti-VEGF Protein Compositions and Methods for Producing the Same (2020)
Regeneron Pharmaceuticals, Inc.
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 11 of these applications claim priority to application 63/065,012, filed Aug 13, 2020. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 12,319,728 | Anti-VEGF Protein Compositions and Methods for Producing the Same In force · Medium confidence UsedRemaining | Regeneron Pharmaceuticals, Inc. | In force | Medium confidence | ||
| US 11,485,770 | Anti-VEGF Protein Compositions and Methods for Producing the Same In force · High confidence | Regeneron Pharmaceuticals, Inc. | In force | High confidence | ||
| US 11,505,593 | Anti-VEGF Protein Compositions and Methods for Producing the Same In force · Medium confidence | Regeneron Pharmaceuticals, Inc. | In force | Medium confidence | ||
| US 11,542,317 | Anti-VEGF Protein Compositions and Methods for Producing the Same In force · Medium confidence | Regeneron Pharmaceuticals, Inc. | In force | Medium confidence | ||
| US 11,753,459 | Anti-VEGF Protein Compositions and Methods for Producing the Same In force · High confidence | Regeneron Pharmaceuticals, Inc. | In force | High confidence | ||
| US 12,012,444 | Anti-VEGF Protein Compositions and Methods for Producing the Same In force · High confidence | Regeneron Pharmaceuticals, Inc. | In force | High confidence | ||
| US 12,054,532 | Anti-VEGF Protein Compositions and Methods for Producing the Same In force · High confidence | Regeneron Pharmaceuticals, Inc. | In force | High confidence | ||
| US 12,338,274 | Anti-VEGF Protein Compositions and Methods for Producing the Same In force · Low confidence | Regeneron Pharmaceuticals, Inc. | In force | Low confidence | ||
| US 11,186,625 | Anti-VEGF Protein Compositions and Methods for Producing the Same In force · Medium confidence | Regeneron Pharmaceuticals, Inc. | In force | Medium confidence | ||
| US 11,306,135 | Anti-VEGF Protein Compositions and Methods for Producing the Same In force · Medium confidence | Regeneron Pharmaceuticals, Inc. | In force | Medium confidence | ||
| 4 more records in this group · Pro | ||||||
10 of 14 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 14, including 1 expiring within the 18 months from Nov 21, 2026.
11 of these are in force and held by Regeneron Pharmaceuticals, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.